STING1 and neoplasm: Treatment of STING−/− mice carrying STING-expressing tumors with the STING agonist ADU-S100 elicited a transient growth impairment of the primary and secondary tumors, whereas STING+/+ mice carrying STING-KO tumors showed complete clearance of the primary tumor along with delayed secondary tumor growth [145].